Kurarinone ameliorates intestinal mucosal inflammation via regulating T cell immunity

Area of Science:

• Pharmacology
• Immunology
• Gastroenterology

Background:

• Inflammatory bowel disease (IBD) presents a growing global health challenge.
• Herbal medicines show promise for IBD management via immune regulation and anti-inflammatory effects.
• Kurarinone (KAR), from Sophora flavescens, has known antioxidant and anti-inflammatory properties, but its IBD therapeutic potential is understudied.

Purpose of the Study:

• To investigate the therapeutic effects of Kurarinone (KAR) on intestinal mucosal inflammation in a mouse model of inflammatory bowel disease (IBD).
• To elucidate the underlying mechanisms of KAR's action, including its impact on gut microbiota and immune cell responses.

Main Methods:

• Colitis was induced in mice using trinitrobenzene sulfonic acid (TNBS).
• Kurarinone (KAR) was administered intraperitoneally.
• Mucosal inflammation was assessed via histology, flow cytometry, and immunofluorescence; gut microbiota by 16S rRNA sequencing; and molecular targets by RNA sequencing and in vitro T cell assays.

Main Results:

• KAR administration mitigated colonic tissue damage and reduced inflammatory cell infiltration (monocytes/macrophages, neutrophils, T lymphocytes) in TNBS-induced colitis mice.
• KAR protected against goblet cell loss and tight junction destruction, while restoring gut microbiota composition.
• Mechanistically, KAR suppressed T helper 17 (Th17) cell responses and promoted interleukin-10 (IL-10) production via Blimp-1.

Conclusions:

• Kurarinone (KAR) demonstrates significant therapeutic potential for inflammatory bowel disease (IBD) by reducing colonic inflammation and restoring gut homeostasis.
• The findings highlight KAR's ability to modulate immune responses and gut microbiota, suggesting novel therapeutic strategies for IBD clinical interventions.